Intellia's Lonvo-z Hits Phase 3 Milestone, Sets 2027 U.S. Launch Timeline
Event summary
- Lonvo-z Phase 3 HAELO trial met primary endpoint, reducing HAE attacks by 87% vs. placebo.
- Intellia initiated rolling BLA submission for Lonvo-z, targeting U.S. launch in first half of 2027.
- MAGNITUDE and MAGNITUDE-2 Phase 3 trials for Nex-z resumed patient screening after FDA lifted clinical holds.
- Company raised $207 million in April 2026 public offering, extending runway into 2028.
- Q1 2026 R&D expenses decreased 25.5% YoY to $80.7 million.
The big picture
Intellia's positive Phase 3 data for Lonvo-z positions it as a potential first-to-market CRISPR-based therapy for HAE, a significant milestone in the gene editing field. The company's ability to secure additional funding and resume critical trials demonstrates operational resilience. Success in these areas could validate the commercial viability of in vivo gene editing technologies.
What we're watching
- Regulatory Pathway
- Whether the FDA's rolling BLA review will maintain accelerated timeline for Lonvo-z approval.
- Commercialization Readiness
- The pace at which Intellia can build out commercial infrastructure ahead of Lonvo-z launch.
- Clinical Trial Execution
- How quickly MAGNITUDE-2 trial for Nex-z can complete enrollment and deliver topline data.
Related topics